NCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
7 trialsNCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT01826864 2020-07-27
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Jonsson Comprehensive Cancer Center
Phase 3 Withdrawn
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT01530984 2015-10-05
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT00446173 2015-08-25
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Withdrawn